BioXcel Therapeutics Inc. (BTAI)
NASDAQ: BTAI
· Real-Time Price · USD
1.72
0.07 (4.24%)
At close: Jun 24, 2025, 3:59 PM
1.83
6.40%
Pre-market: Jun 25, 2025, 07:19 AM EDT
4.24% (1D)
| Bid | 1.8 |
| Market Cap | 10.42M |
| Revenue (ttm) | 1.85M |
| Net Income (ttm) | -40.06M |
| EPS (ttm) | -11.12 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -0.24 |
| Analyst | Buy |
| Ask | 1.9 |
| Volume | 75,669 |
| Avg. Volume (20D) | 223,858 |
| Open | 1.78 |
| Previous Close | 1.65 |
| Day's Range | 1.63 - 1.83 |
| 52-Week Range | 1.17 - 25.12 |
| Beta | -0.13 |
About BTAI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BTAI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BTAI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
BioXcel Therapeutics Inc. is scheduled to release its earnings on Aug 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+7.73%
BioXcel Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
3 months ago
+22.99%
BioXcel Therapeutics shares are trading higher after the company announced it has reached 33% enrollment in its 200-patient SERENITY At-Home trial.
1 week ago · https://www.defenseworld.net
Squarepoint Ops LLC Acquires 48,336 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)Squarepoint Ops LLC grew its stake in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) by 203.9% during the fourth quarter, according to the company in its most recent 13F filing...
